A Single-Center, Randomized, Controlled, Masked Clinical Trial to Evaluate the Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation (The IMPERIAL Study)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Varenicline (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Acronyms The IMPERIAL Study
- Sponsors Oyster Point Pharmaceuticals
- 28 Oct 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.
- 28 Oct 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Feb 2020.
- 28 Oct 2019 Status changed from recruiting to active, no longer recruiting.